EMP-1 promotes tumorigenesis of NSCLC through PI3K/AKT pathway

被引:0
作者
Senyan Lai
Guihua Wang
Xiaonian Cao
Zhaoming Li
Junbo Hu
Jing Wang
机构
[1] Huazhong University of Science and Technology,Cancer Research Institute, Tongji Hospital, Tongji Medical College
来源
Journal of Huazhong University of Science and Technology [Medical Sciences] | 2012年 / 32卷
关键词
NSCLC; EMP-1 gene; PI3K/AKT pathway; tumorigenesis;
D O I
暂无
中图分类号
学科分类号
摘要
This study examined the role of EMP-1 in tumorigenesis of non-small cell lung carcinoma (NSCLC) and the possible mechanism. Specimens were collected from 28 patients with benign lung diseases and 28 with NSCLC, and immunohistochemically detected to evaluate the correlation of EMP-1 expression to the clinical features of NSCLC. Recombinant adenovirus was constructed to over-express EMP-1 and then infect PC9 cells. Cell proliferation was measured by Ki67 staining. Western blotting was performed to examine the effect of EMP-1 on the PI3K/AKT signaling. Moreover, tumor xenografts were established by subcutaneous injection of PC9 cell suspension (about 5×107/mL in 100 μL of PBS) into the right hind limbs of athymic nude mice. The results showed EMP-1 was significantly up-regulated in NSCLC patients as compared with those with benign lung diseases. Over-expression of EMP-1 promoted proliferation of PC9 cells, which coincided with the activation of the PI3K/AKT pathway. EMP-1 promoted the growth of xenografts of PC9 cells in athymic nude mice. It was concluded that EMP-1 expression may contribute to the development and progress of NSCLC by activating PI3K/AKT pathway.
引用
收藏
页码:834 / 838
页数:4
相关论文
共 95 条
[1]  
Jemal A.(2008)Cancer statistics, 2008 CA Cancer J Clin 58 71-96
[2]  
Siegel R.(2004)EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497-1500
[3]  
Ward E.(2004)Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2129-2139
[4]  
Paez J.G.(2004)EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci USA 101 13306-13311
[5]  
Janne P.A.(2008)Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting J Clin Oncol 26 983-994
[6]  
Lee J.C.(2008)Acquired resistance to tyrosine kinase inhibitors during cancer therapy Curr Opin Genet Dev 18 73-79
[7]  
Lynch T.J.(2005)KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib PLoS Med 2 e17-792
[8]  
Bell D.W.(2005)EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N Engl J Med 352 786-6501
[9]  
Sordella R.(2006)Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors Clin Cancer Res 12 6494-5769
[10]  
Pao W.(2006)Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib Clin Cancer Res 12 5764-1043